Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


An Emerging REMS Dilemma: Qnexa, Truvada – and Korlym

This article was originally published in RPM Report

Executive Summary

Two high-profile applications pose a thorny dilemma for FDA: how to impose a REMS for a new indication without restricting access for already approved uses where restrictions are not appropriate. That same issue didn’t seem to slow the agency down on a recent approval decision involving a very controversial ingredient.


Related Content

Gilead Builds Adherence Trial and Behavior Profiling Data Into Truvada PrEP Approval
FDAAA Impact Analysis (Year 4): The REMS Retreat Continues - For Now
Two Indications, One REMS: FDA Panel Debates Restricted Access For Truvada In PrEP
Setting the Stage: Qnexa and the Power of REMS


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts